Program
Time Table
Available in both live streaming and on-demand streaming
Live Streaming: February 18 (Thu) -21 (Sun), 2021
On-demand Streaming: March 1 (Mon)- 31 (Wed), 2021
* Note that Sponsored Seminar and the sessions which are required to make pre-registration will not be available in on-demand streaming.
Time Table, Day 1,
February 18 (Thu)
Time Table, Day 2,
February 19 (Fri)
Available in on-demand streaming
On-demand Streaming: March 1 (Mon)- 31 (Wed), 2021
Program
Presidential Session
Presidential Session 1
February 19 (Fri) 14:00-15:55
Presidential Session 1
Chairs: |
Tae Won Kim (Asan Medical Center, Korea) |
| Yuichiro Ohe (National Cancer Center Hospital) |
| PS1-1 | First-Line Pembrolizumab+Chemotherapy for Advanced Esophageal Carcinoma in Global and Japanese Patients: KEYNOTE-590 |
|---|---|
| Hiroki Hara (Saitama Cancer Center, Saitama) |
| PS1-2 | Pembrolizumab vs chemotherapy for MSI-high/dMMR metastatic colorectal cancer: Asia subgroup of phase 3 KEYNOTE-177 |
|---|---|
| Takayuki Yoshino (National Cancer Center Hospital East) |
| PS1-3 | Phase III trial of nivolumab + platinum chemotherapy + bevacizumab in untreated advanced NSQ NSCLC: Japanese subanalysis |
|---|---|
| Toyoaki Hida (Department of Thoracic Oncology, Aichi Cancer Center) |
| PS1-4 | Two phase II trials of PD-1 inhibitors in patients with pulmonary sarcomatoid carcinoma (NCCH1603/NCCH1703) |
|---|---|
| Kota Itahashi (Department of Thoracic Oncology, National Cancer Center Hospital) |
| PS1-5 | Updated results from phase 1 dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in R/R AML patients |
|---|---|
| Farhad Ravandi (Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA) |
Presidential Session 2
February 20 (Sat) 15:30-17:35
Presidential Session 2
Chairs: |
Elaine Lim (National Cancer Centre Singapore, Singapore) |
| Chikashi Ishioka (Department of Clinical Oncology, Tohoku University Graduate School of Medicine) |
| PS2-1 | Phase II/III Trial of Post-operative Chemoradiotherapy Comparing 3-Weekly Cisplatin with Weekly Cisplatin in High-risk Patients with Squamous Cell Carcinoma of the Head and Neck（JCOG1008） |
|---|---|
| Makoto Tahara (National Cancer Center Hospital East) |
| PS2-2 | Overall survival and ctDNA analysis of bevacizumab plus erlotinib treatment for EGFR-mutant NSCLC patients in NEJ026 |
|---|---|
| Tatsuro Fukuhara (Miyagi Cancer Center) |
| PS2-3 | PRECIOUS: Pertuzumab re-treatment for HER2-positive locally advanced/metastatic breast cancer (JBCRG-M05) |
|---|---|
| Tatsuya Toyama (Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences) |
| PS2-4 | Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: phase 2 innovaTV 204 study results |
|---|---|
| Robert L. Coleman (US Oncology Research, The Woodlands, Houston, TX, USA) |
| PS2-5 | CodeBreak 100: Activity of AMG 510, a novel KRASG12C inhibitor, in patients with advanced colorectal cancer |
|---|---|
| Yasutoshi Kuboki (Department of Experimental Therapeutics and GI Oncology, National Cancer Center Hospital East, Kashiwa, Japan) |
Presidential Session 3
February 21 (Sun) 14:50-16:50
Presidential Session 3
Chairs: |
Prunella Blinman (MOGA President / Medical Oncology, Concord Repatriation General Hospital, Australia) |
| Kazuto Nishio (Department of Genome Biology, Kindai University Faculty of Medicine) |
| PS3-1 | Genomic Alterations in Circulating Tumor DNA (ctDNA) in Advanced Gastrointestinal Cancers: SCRUM-Japan MONSTAR-SCREEN |
|---|---|
| Toshiki Masuishi (Department of Clinical Oncology, Aichi Cancer Center Hospital) |
| PS3-2 | Genomic characterization of circulating tumor DNA in advanced genitourinary cancer patients SCRUM-Japan MONSTAR SCREEN |
|---|---|
| Norio Nonomura (Department of Urology, Osaka University Graduate School of Medicine) |
| PS3-3 | The Initial Expert Panel Performance in Core Hospitals for Cancer Genomic Medicine in Japan |
|---|---|
| Kuniko Sunami (Department of Laboratory Medicine, National Cancer Center Hospital) |
| PS3-4 | Phase II Trial of Site-Specific Treatment Based on Gene Expression and Mutation Profiling by NGS for Patients with CUP |
|---|---|
| Makoto Arai (Department of Medical Oncology, Graduate School of Medicine, Chiba University) |
| PS3-5 | Phase III study of palonosetron for preventing chemotherapy-induced nausea and vomiting in pediatric patients |
|---|---|
| Yuhki Koga (Department of Pediatrics, Kyushu University) |
Presidential Symposium
Presidential Symposium 1 [Precision Oncology 1]
February 19 (Fri) 8:00-9:40
Precision Oncology in Solid Cancer (I)
Summary
We will discuss agnostic approaches that go beyond national, regional, and organ-specific methods by learning about the current and near future of Precision Oncology using gene panel tests. This symposium is an agonistic session that integrates themes proposed by the JSMO Academic Planning Committee (JSMO-APC)
Chairs: |
Bruce E. Johnson (Dana-Farber Cancer Institute, USA) |
| Junji Tsurutani (Advanced Cancer Translational Research Institute, Showa University) |
| PSY1-1 | The Framework of Cancer Precision Medicine in Japan |
|---|---|
| Yasushi Yatabe (Department of Diagnostic Pathology, National Cancer Center Hospital) |
| PSY1-2 | Expanding the Reach of Precision Medicine in Lung Cancer |
|---|---|
| Bruce E. Johnson (Dana-Farber Cancer Institute, USA) |
| PSY1-3 | Precision medicine in lung cancer |
|---|---|
| Masayuki Takeda (Department of Medical Oncology, Kindai University) |
| PSY1-4 | Cancer gene panel test for metastatic breast cancer: Current status and future perspectives |
|---|---|
| Hiroshi Tada (Department of Breast and Endocrine Surgical Oncology, Tohoku University) |
| PSY1-5 | Precision medicine in gynecological cancer |
|---|---|
| Katsutoshi Oda (Division of Integrative Genomics, The University of Tokyo) |
Presidential Symposium 8 [Precision Oncology 2]
February 20 (Sat) 21:00-22:30
Precision Oncology in Solid Cancer (II)
Chairs: |
Eishi Baba (Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University) |
| John Bridgewater (UCL Cancer Institute, UK) |
| PSY8-1 | Precision Medicine in Gastric Cancer - Opportunities and Challenges |
|---|---|
| Patrick Tan (Duke-NUS Medical School, Singapore) |
| PSY8-2 | Search of biomarkers and creation of innovative methods required for precision medicine for gastric cancer |
|---|---|
| Hirokazu Shoji (Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital) |
| PSY8-3 | Precision Medicine in biliary tract cancer |
|---|---|
| John Bridgewater (UCL Cancer Institute, UK) |
| PSY8-4 | Targeting unique vulnerabilities in sarcomas as a therapeutic paradigm |
|---|---|
| George Demetri (Dana-Farber Cancer Institute/ Ludwig Center/ Harvard Medical School, USA) |
Presidential Symposium 7
[Asian International Collaboration Symposium]
February 20 (Sat) 15:30-17:10
Current Status and Future Perspectives for Biliary Tract Cancer in Asian Countries
Summary
This session will review the epidemiological status of biliary tract cancer in Asia, the current state of treatments, and the prospects for disease management. After the conference, we will prepare a paper on the subject for publication in a scientific journal.
Chairs: |
Junji Furuse (Department of Medical Oncology, Kyorin University Faculty of Medicine) |
| Masafumi Ikeda (National Cancer Center Hospital East) |
| PSY7-1 | The current situation of chemotherapy regarding biliary tract cancer in Japan |
|---|---|
| Makoto Ueno (Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center) |
| PSY7-2 | Precision medicine for biliary tract cancer |
|---|---|
| Chigusa Morizane (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital) |
| PSY7-3 | Adjuvant, conversion, and neoadjuvant therapy for biliary tract cancer |
|---|---|
| Etsuro Hatano (Department of Gastroenterological Surgery, Hyogo College of Medicine) |
| PSY7-4 | Current status and future perspectives in biliary tract cancer in Singapore |
|---|---|
| Su Pin Choo (Curie Oncology, Singapore) |
| PSY7-5 | Current status and future perspectives in biliary tract cancer in Korea |
|---|---|
| Do-Youn Oh (Divsion of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Korea) |
Presidential Symposium 6
[Asian International Collaboration Symposium]
February 20 (Sat) 15:30-17:10
Challenges of Breast Cancer Research Collaboration Across Asia
Summary
We will discuss how to organize investigator-led clinical trials in Japan and East/South-East Asia, including epidemiology, clinical practice, and operating system of the clinical trials of each country, and prospects for the future development of novel treatment across Asia.
Chairs: |
Shinji Ohno (Breast Oncology Center, Cancer Institute Hospital of JFCR) |
| Yoon-Sim Yap (Division of Medical Oncology, National Cancer Centre Singapore, Singapore) |
| PSY6-1 | The future perspective of Asian collaboration based on experience of investigator initiated global clinical trials (PENELOPE-B and PALLAS) |
|---|---|
| Hiroji Iwata (Aichi Cancer Center Hospital) |
| PSY6-2 | International research collaboration at the KSCG |
|---|---|
| Seock-Ah Im (Seoul National University, Korean Cancer Study Group, Korea) |
| PSY6-3 | International research collaboration in Singapore |
|---|---|
| Yoon-Sim Yap (Division of Medical Oncology, National Cancer Centre Singapore, Singapore) |
| PSY6-4 | Regulatory aspect of regional collaboration for medical products development in Asia |
|---|---|
| Daisuke Koga (Division of Planning and Management, Office of International Programs, PMDA) |
| PSY6-5 | Challenges of gynecologic cancer research with Asian countries |
|---|---|
| Kazuki Sudo (Dept. of Breast and Medical Oncology / Dept. of Experimental Therapeutics / Dept. of International Clinical Development / Rare Cancer Center, National Cancer Center Hospital) |
Presidential Symposium 4
[Asian International Collaboration Symposium]
February 20 (Sat) 9:00-10:40
Facilitation of Asian Collaboration in Cancer Clinical Trials
Summary
The formation of a clinical trial network with Asian countries plays an extremely important role in order to increase the presence of Asia as the third pole following the U.S. and Europe, and to increase the role of the Japanese Society of Medical Oncology among academic community in Asia. The Japanese government is reinforcing the Asian Human Well-Being Initiative and AMED has recently launched the Asian Clinical Trials Network Project. In this session, we will invite speakers from Asian countries and discuss the future prospects for the Asian collaboration in clinical trials.
Chairs: |
Kenichi Nakamura (Clinical Research Support Office, National Cancer Center Hospital) |
| Tatsuo Iiyama (Department of International Trials, National Center for Global Health and Medicine (MCGM)) |
| PSY4-1 | MHLW's key initiatives based on Grand Design for Asian Pharaceutical and medical Device Regulatory Harmonization |
|---|---|
| Junya Kasamatsu (Ministry of Health, Labour and Welfare, Director Research and Development Division Health Policy Bureau) |
| PSY4-2 | PMDA's activities to promote regulatory convergence in Asia |
|---|---|
| Junko Sato (Pharmaceuticals and Medical Devices Agency) |
| PSY4-3 | The beginning of the ATLAS project |
|---|---|
| Kan Yonemori (National Cancer Center Hospital) |
| PSY4-4 | Clinical Oncology Research Environment in Malaysia: Now and Future |
|---|---|
| Akhmal Yusof (Clinical Research Malaysia, Malaysia) |
| PSY4-5 | Challenges of Cancer Clinical Trials in Viet Nam |
|---|---|
| Pham Tuan Anh (Department of Medical Oncology, National Cancer Hospital of Vietnam, Vietnam) |
ASCO-JSMO Breakthrough Meeting Insights
February 20 (Sat) 8:00-9:30
Artificial Intelligence in Oncology and Therapeutics
| Chair: | Rebecca Dent (Breast Cancer National Cancer Centre Singapore, Singapore) |
| PSY3-1 | Artificial Intelligence in Oncology Imaging |
|---|---|
| A. Gregory Sorensen (DeepHealth, Inc., USA) |
| PSY3-2 | Artificial Intelligence for Cancer Diagnosis and Treatment |
|---|---|
| Brandon Suh (Lunit, Inc., Korea) |
| PSY3-3 | AI for Precision Oncology |
|---|---|
| Manabu Muto (Department of Therapeutic Oncology, Kyoto University) |
| PSY3-4 | AI for Practice |
|---|---|
| Melvin Lee Kiang Chua (Division of Radiation Oncology, National Cancer Centre Singapore / Tan Chin Tuan Laboratory of Optical Imaging, Photodynamic and Proton Therapy & Precision Radiation Oncology Programme, National Cancer Centre Singapore / Duke-NUS Medical School, Singapore / Wuhan University Zhongnan Hospital, China) |
Special Session
Special Session 2
February 21 (Sun) 8:00-10:00
Impact of COVID-19 on Clinical Practice and Research in Oncology
Summary
As of November 5, 2020, over 47.9 million people worldwide have been infected with the new corona pneumonia virus and 1.22 million people, including health care workers, have lost their lives. We would like to express our condolences to those who have died from this disease and send our support to all healthcare workers working on the front lines of medicine for infectious diseases.
The new coronavirus disease (COVID-19) has had a profound impact on the world, from economy to politics and has understandably disrupted cancer care and clinical research, bringing to light the need to improve and refine existing cancer care and clinical trial methods and the need to introduce new approaches. In this symposium, two speakers from Japan and two speakers from overseas will discuss the impact of COVID-19 on both cancer treatment and clinical research and how to cope with it. We hope that this forum will be a place where all participants, including the presenters, can gain insights into cancer treatment in the post-corona era and new strategies to clinical research.
Chairs: |
Jiichiro Sasaki (Division of Clinical Oncology, Department of Comprehensive Medicine, Research and Development Center for New Medical Frontier, Kitasato University School of Medicine) |
| Hidehito Horinouchi (Department of Thoracic Oncology, National Cancer Center Hospital) |
| SP2-1 | The impact of COVID-19 on cancer treatment in Japan; actual condition, countermeasure, and task |
|---|---|
| Yu Sunakawa (Department of Clinical Oncology, St. Marianna University School of Medicine) |
| SP2-2 | COVID-19 Impact on the Oncology Practice in the USA |
|---|---|
| Naoto T. Ueno (Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, USA) |
| SP2-3 | The impact of the COVID-19 global pandemic on oncology drug development, clinical research and R&D in Japan |
|---|---|
| Toshio Shimizu (Early Phase 1 Drug Development Service, Department of Experimental Therapeutics, National Cancer Center Hospital ) |
| SP2-4 | Impact of COVID-19 on clinical practice and research in oncology in Singapore- experience of the National University Cancer Institute |
|---|---|
| Ross A. Soo (National University Cancer Institute, Singapore ) |
Joint Symposium
ASCO/JSMO Joint Symposium
February 19 (Fri) 8:00-10:00
AI Oncology: Development Status and Perspectives
Chairs: |
Takayuki Yoshino (National Cancer Center Hospital East) |
| Howard A. Burris (Chair ASCO / Sarah Cannon, USA) |
| AJS-1 | Identifying Subgroups at High-risk of ICI Associated Cardiac Adverse Events: an Approach Using Topological Data Analysis |
|---|---|
| Samuel Heilbroner (ConcertAI, USA) |
| AJS-2 | AI Trends and Impacts for Global Oncology Life Science Companies |
|---|---|
| Lauren Becnel (Department of Patient and Health Impact, Pfizer Inc., USA) |
| AJS-3 | Incorporating AI into Oncology Practice: Opportunities and Challenges |
|---|---|
| Howard A. Burris (Chair ASCO / Sarah Cannon, USA) |
| AJS-4 | AI consultation for NGS results |
|---|---|
| Hiroshi Nishihara (Genomics Unit, Keio Cancer Center, Keio University School of Medicine) |
| AJS-5 | Forefront Challenge in the SCRUM-Japan utilizing Artificial Intelligence (AI) - Virtual Sequencing (VSQ) and QA Commons (QAC) Projects and Beyond |
|---|---|
| Takayuki Yoshino (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East) |
ESMO/JSMO Joint Symposium
February 18 (Thu) 16:00-18:00
Liquid Biopsy for Clinical Implementation
Chairs: |
Chikashi Ishioka (Department of Clinical Oncology, Tohoku University Graduate School of Medicine) |
| Solange Peters (ESMO President /Centre Hospitalier Universitaire Vaudois, Lausanne University, Switzerland) |
| EJS-1 | Clinical utility of analyzing ctDNA in patients with metastatic colorectal cancer |
|---|---|
| Josep Tabernero (Vall d'Hebron University Hospital / Vall d'Hebron Institute of Oncology (VHIO), Spain) |
| EJS-2 | Clinical utility of analyzing ctDNA in patients with Lung cancers |
|---|---|
| Solange Peters (ESMO President /Centre Hospitalier Universitaire Vaudois, Lausanne University, Switzerland) |
| EJS-3 | Adjuvant treatment for colon cancer and the emerging role of ctDNA as an MRD marker |
|---|---|
| Julien Taieb (Université Paris Descartes, Paris, France) |
| EJS-4 | A large scale prospective concordance study between plasma cell-free DNA and tissue based NGS analysis in advanced non-small cell lung cancer (NSCLC) |
|---|---|
| Koichi Goto (Department of Thoracic Oncology, National Cancer Center Hospital East) |
| EJS-5 | ctDNA&beyond in urological tumors |
|---|---|
| Shusuke Akamatsu (Department of Urology, Kyoto University) |
| EJS-6 | Current and Future Paradigms of Circulating Tumor DNA Analysis in All Stages of Cancer Care |
|---|---|
| Yoshiaki Nakamura (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East) |
Asia-Pacific/JSMO Joint Symposium
February 21 (Sun) 9:00-11:00
CAR-T and New Generation Therapy in Asia-Pacific
Chairs: |
Hitoshi Kiyoi (Department of Hematology and Oncology, Nagoya University Graduate School of Medicine) |
| Stephan Grupp (Cellular Therapy and Transplant, Children’s Hospital of Philadelphia, USA) |
| APJS-1 | Current status and future perspectives on CAR-T therapy in the United States |
|---|---|
| Stephan Grupp (Cellular Therapy and Transplant, Children’s Hospital of Philadelphia, USA) |
| APJS-2 | Updates in Research for CAR-T therapy in China |
|---|---|
| Zonghai Li (Shanghai Cancer Institute / CARsgen Therapeutics, China) |
| APJS-3 | The Australian Experience of Commerical CAR-T implementation |
|---|---|
| Michael Dickinson (Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Australia) |
| APJS-4 | CAR-T cell therapy for hematological malignancies in Japan ～importance of collaboration of intra～ and inter-institutions |
|---|---|
| Hidefumi Hiramatsu (Department of Pediatrics, Graduate School of Medicine Kyoto University) |
| APJS-5 | Development of new CAR-T therapy in Japan |
|---|---|
| Koji Tamada (Department of Immunology, Yamaguchi University Graduate School of Medicine) |
SIOG/JSMO Joint Symposium
February 18 (Thu) 21:00-23:00
The Geriatric Oncology, Past, Present and Future
Chairs: |
Etienne Brain (Department of Medical Oncology, Institut Curie-Hôpital René Huguenin, France) |
| Tomonori Mizutani (Department of Medical Oncology, Kyorin University Faculty of Medicine) |
| SJS-1 | Top priorities for the global advancement of cancer in order adults and application to breast cancer |
|---|---|
| Etienne Brain (Department of Medical Oncology, Institut Curie-Hôpital René Huguenin, France) |
| SJS-2 | Approaches to Geriatric Oncology in Japan |
|---|---|
| Tomonori Mizutani (Department of Medical Oncology, Kyorin University Faculty of Medicine) |
| SJS-3 | An Update on Geriatric Oncology Trials in the United States |
|---|---|
| Supriya G. Mohile (University of Rochester Medical Center, USA) |
| SJS-4 | Current status and future prospects of clinical trials on geriatric assessments of older lung cancer patients in Japan |
|---|---|
| Yukari Tsubata (Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Shimane University Faculty of Medicine) |
| SJS-5 | Geriatric Oncology in super-aged society of Japan (Basic Plan to Promote Cancer Control Programs and SDGs Action Plan 2020) |
|---|---|
| Fumio Nagashima (Department of Medical Oncology, Kyorin University Faculty of Medicine) |
Symposium
Gastrointestinal Cancer
Symposium 8 [Gastrointestinal Cancer]
February 18 (Thu) 21:20-23:00
Future Perspectives of Immunotherapy for mCRC
Summary
To discuss the status and prospects for the development of immunotherapy for colorectal cancer.
Chairs: |
Kohei Shitara (National Cancer Center Hospital East) |
| Josep Tabernero (Vall d'Hebron University Hospital / Vall d'Hebron Institute of Oncology (VHIO), Spain) |
| SY8-1 | Rationale of immunotherapy for CRC |
|---|---|
| Josep Tabernero (Vall d'Hebron University Hospital / Vall d'Hebron Institute of Oncology (VHIO), Spain) |
| SY8-2 | Microbiome and its significance in immunotherapy for CRC |
|---|---|
| Shota Fukuoka (Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center) |
| SY8-3 | Regorafenib plus Nivolumab for Colorectal Cancer |
|---|---|
| Kohei Shitara (National Cancer Center Hospital East) |
| SY8-4 | TAS116+Nivolumab for MSS CRC |
|---|---|
| Akihito Kawazoe (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East) |
| SY8-5 | Preoperative Chemoradiotherapy plus Consolidation Nivolumab followed by Radical Surgery in Patients with Locally Advanced Rectal Cancer |
|---|---|
| Hideaki Bando (Department of Clinical Oncology, Aichi Cancer Center) |
Symposium 17 [Gastrointestinal Cancer]
February 19 (Fri) 20:30-22:10
Current Status and Future Perspectives of Immunotherapy for Advanced Gastric Cancer
Summary
To discuss expectations of new strategies to manage gastric cancer from recent data.
Chairs: |
Takako Nakajima (Kyoto Innovation Center for Next Generation Clinical Trials and iPS Cell Therapy) |
| Ian Chau (Department of Medicine, The Royal Marsden Hospital, UK) |
| SY17-1 | Keynote lecture: present status of immunotherapy for advanced gastric cancer |
|---|---|
| Ian Chau (Department of Medicine, The Royal Marsden Hospital, UK) |
| SY17-2 | Regorafenib plus Nivolumab or Lenvatinib plus Pembrolizumab for Gastric Cancer |
|---|---|
| Kohei Shitara (National Cancer Center Hospital East) |
| SY17-3 | Gut Microbiome |
|---|---|
| Yu Sunakawa (Department of Clinical Oncology, St. Marianna University School of Medicine) |
| SY17-4 | Immuno Oncology agents for advanced gastric cancer |
|---|---|
| Eric Van Cutsem (University Hospital Leuven, Belgium) |
| SY17-5 | Potential biomarkers for immunotherapy of gastric cancer |
|---|---|
| Yutaka Kawakami (Department of Immunology, School of Medicine, International University of Health and Welfare／Division of Cellular Signaling Institute for Advanced Medical Research, Keio University School of Medicine) |
Symposium 5 [Gastrointestinal Cancer]
February 18 (Thu) 16:45-18:00
Current Status and Future Perspectives of Immunotherapy for Advanced Esophageal Cancer
Summary
For several years, there have been no new drugs available for esophageal cancer and no phase III trials have been reported. Recently, the KEYNOTE181 and OPRA phase III trials have reported the superiority of ICI vs chemotherapeutic regimens as second-line therapy and the results of ICI as first-line treatment are also expected to be published later this year. Moreover, approval of nivolumab as second-line therapy based is expected next year based on the results of an expanded clinical trial. Thus, this is the best time to review the status and prospects of immunotherapy for esophageal cancer.
Chairs: |
Taroh Satoh (FRONTIER Science for Cancer and Chemotherapy Osaka University Graduate School of Medicine) |
| Florian Lordick (University Cancer Center Leipzig, Germany) |
| SY5-1 | Biology of esophageal cancer |
|---|---|
| Florian Lordick (University Cancer Center Leipzig (UCCL), University of Leipzig Medical Center, Leipzig, Germany) |
| SY5-2 | First line immunocheckpoint inhibitors for esophageal cancer |
|---|---|
| Ken Kato (Department of Head and Neck Medical Oncology, National Cancer Center Hospital) |
| SY5-3 | Recent advances in second-line treatment for unresectable advanced or recurrent esophageal cancer |
|---|---|
| Toshihiro Kudo (Department of Medical Oncology, Osaka International Cancer Institute) |
| SY5-4 | Biomarker for immunotherapy in esophageal cancer |
|---|---|
| Takashi Kojima (National Cancer Center Hospital East, Department of Gastroenterology and Gastrointestinal Oncology) |
| SY5-5 | Real-World Data in the Era of Immune Checkpoint Inhibitors |
|---|---|
| Yukiya Narita (Department of Clinical Oncology, Aichi Cancer Center Hospital) |
Hepatobiliary/Pancreatic Cancer
Symposium 21 [Hepatobiliary/Pancreatic Cancer]
February 19 (Fri) 20:30-22:30
Cutting-Edge Perioperative Treatments for Pancreatic Cancer
Summary
Peri-operative adjuvant chemotherapy as standard treatment for pancreatic cancer has changed significantly with the introduction of FOLFIRINOX adjuvant therapy (as reported from abroad) and neoadjuvant chemotherapy with gemcitabine and S1 (as reported from Japan). As a result, there are more therapeutic options for patients with unresectable pancreatic cancers and there is much debate on the indication and effectiveness of these treatments. In this session, we will review the current status in Japan and other countries and discuss the future development of treatment strategies.
Chairs: |
Makoto Ueno (Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center) |
| Takuji Okusaka (National Cancer Center Hospital) |
| SY21-1 | Perioperative chemotherapy in pancreatic ductal adenocarcinoma: the more the better? |
|---|---|
| Thierry Conroy (Department of Medical Oncology, institut de cancerologie de Lorraine, France) |
| SY21-2 | Perioperative treatments for pancreatic cancer in Taiwan |
|---|---|
| Li-Tzong Chen (TOS President / National Institute of Cancer Research, Taiwan) |
| SY21-3 | Perioperative treatments for resectable pancreatic ductal adenocarcinoma |
|---|---|
| Shohei Satoi (Department of Surgery, Kansai Medical University) |
| SY21-4 | Perioperative treatments for borderline resectable pancreatic cancer |
|---|---|
| Shinichiro Takahashi (Clinical Research Support Office/ Department of Hepato-Biliary-Pancreatic Surgery, National Cancer Center Hospital East) |
| SY21-5 | Conversion surgery in unresectable pancreatic cancer - Surgery perspectives - |
|---|---|
| Hidenori Takahashi (Department of Gastroenterological Surgery, Osaka International Cancer Institute) |
| SY21-6 | Conversion surgery in unresectable pancreatic cancer- Medical oncology perspectives |
|---|---|
| Masato Ozaka (Cancer Institute Hospital of JFCR) |
Symposium 26 [Hepatobiliary/Pancreatic Cancer]
February 20 (Sat) 10:30-12:30
Systemic Therapy for Advanced Hepatocellular Carcinoma- New Standards and Future Perspectives
Summary
Several new drug therapies have become available for patients with hepatocellular carcinoma (HCC). However, several questions remain unanswered. Here, we will discuss issues such as sequential therapy and treatment choice for HCC patients with reduced liver reserve and severe vascular invasion.
Chairs: |
Tatsuya Yamashita (Advanced preventive medical sciences research center Kanazawa University) |
| Manabu Morimoto (Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center) |
| SY26-1 | First line treatments against unresectable hepatocellular carcinoma at early 2021 |
|---|---|
| Atsushi Hiraoka (Gastroenterology Center, Ehime Prefectural Central Hospital) |
| SY26-2 | Optimal administration of molecular-targeted agents as secondary treatment for advanced hepatocellular carcinoma |
|---|---|
| Masahito Nakano (Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine) |
| SY26-3 | Systemic chemotherapy for intermediate-stage hepatocellular carcinoma |
|---|---|
| Kazuomi Ueshima (Kindai University Faculty of Medicine Department of Gastroenterology and Hepatology) |
| SY26-4 | Medical treatment for patients with hepatocellular cadrcinoma and Child-Pugh B cirrhosis |
|---|---|
| Takeshi Terashima (Department of Gastroenterology, Kanazawa University Hospital) |
| SY26-5 | Systemic therapies for advanced hepatocellular carcinoma patients with macrovascular invasion |
|---|---|
| Sadahisa Ogasawara (Department of Gastroenterology, Graduate School of Medicine, Chiba University) |
| SY26-6 | Immunotherapy for Hepatocellular Carcinoma |
|---|---|
| Masafumi Ikeda (Department of Hepatobiliary & Pancreatic Oncology, National Cancer Center Hospital East) |
Lung Cancer/Thoracic Cancer
Symposium 4 [Lung Cancer/Thoracic Cancer]
February 18 (Thu) 16:30-18:00
Challenges of Combination Immunotherapy for Lung Cancer
Summary
Combination therapy with immune checkpoint inhibitors (ICI) and other cancer drugs have become available and are being developed for lung cancer and other thoracic malignancies. In addition to combination therapy with cytotoxic anticancer agents and angiogenesis inhibitors, which are already the standard treatments for lung cancer, combination therapy of ICI with other ICIs will be introduced to the clinic. This session will focus on discussing the current state and challenges that lie ahead for the rapidly evolving landscape of combined immunotherapies with experts from Japan and abroad.
Chairs: |
Hidehito Horinouchi (Department of Thoracic Oncology, National Cancer Center Hospital) |
| Martin Reck (Department of Thoracic Oncology, LungenClinic, Germany) |
| SY4-1 | Combination immunotherapy using Anti-PD-1/PD-L1 plus Anti-CTLA-4 antibodies |
|---|---|
| Martin Reck (Department of Thoracic Oncology, LungenClinic, Germany) |
| SY4-2 | Immune checkpoint inhibition in malignant pleural mesothelioma and thymic epithelial tumors |
|---|---|
| Keunchil Park (Div of Hematology-Oncology, Samsung Med Ctr, Sungkyunkwan University School of Medicine, Korea) |
| SY4-3 | Combination immunotherapy in small-cell lung cancer |
|---|---|
| Toshiyuki Kozuki (Department of Thoracic Oncology and Medicine, National Hospital Organization Shikoku Cancer Center) |
| SY4-4 | Immune checkpoint inhibitors in perioperative treatment in lung cancer |
|---|---|
| Hidehito Horinouchi (Department of Thoracic Oncology, National Cancer Center Hospital) |
Symposium 10 [Lung Cancer/Thoracic Cancer]
February 19 (Fri) 8:00-10:00
Perspectives in Translational Biomarker Research for Immune Checkpoint Inhibitors
Summary
A variety of therapeutic strategies using immune checkpoint inhibitors, including combination therapies, have been developed in recent years. Unfortunately, the proportion of patients who achieve durable response is still limited. Various biomarkers have been proposed for predicting the efficacy of ICI therapy. In this session, we will discuss opportunities and challenges of current biomarkers as well as those currently being developed.
Chairs: |
Hidetoshi Hayashi (Department of Medical Oncology, Kindai University) |
| Junya Fujimoto (Department of Translational Molecular Pathology, UT MD Anderson Cancer Center, USA) |
| SY10-1 | The emerging role of cell-free DNA as a biomarker for cancer immunotherapy |
|---|---|
| Caicun Zhou (Department of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, China) |
| SY10-2 | Neoantigenic potential of chromosomal rearrangements, and effects of filtering on tumor mutation burden estimates |
|---|---|
| Aaron S. Mansfield (Mayo Clinic, USA) |
| SY10-3 | Gene expression profiling as the biomarker for immune-checkpoint inhibitors |
|---|---|
| Hidetoshi Hayashi (Department of Medical Oncology, Kindai University) |
| SY10-4 | Clinical biomarkers to predict the efficacy of immune checkpoint inhibitors |
|---|---|
| Satoru Miura (Department of Internal Medicine, Niigata Cancer Center Hospital) |
| SY10-5 | Pathological contribution for Profiling Immune Contexture |
|---|---|
| Junya Fujimoto (Department of Translational Molecular Pathology, UT MD Anderson Cancer Center, USA) |
Symposium 28 [Lung Cancer/Thoracic Cancer]
February 20 (Sat) 21:00-22:30
Future Prospects of Molecular Targeted Therapy for Lung Cancer Patients with Driver Mutations
Summary
Since the discovery of the first EGFR mutation in 2004, drug therapies for lung cancer have improved dramatically and continue to do so with the discoveries of multiple driver gene mutations and the development of molecularly targeted therapies that target them. Approved molecular targeting drugs cover a wide variety of gene alterations, thus, multiplexed genomic testing with low false negative rates is key for establishing new treatment strategies for patients with lung cancer. Utilizing multiple molecularly targeted therapies to target different gene abnormalities is another important factor to consider for maximizing clinical benefit. This session will focus on these discussion points.
Chairs: |
Isamu Okamoto (Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University) |
| Pasi A. Janne (Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, USA) |
| SY28-1 | New therapeutic strategies for EGFR mutant lung cancer |
|---|---|
| Pasi A. Janne (Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, USA) |
| SY28-2 | ALK |
|---|---|
| Solange Peters (ESMO President / Centre Hospitalier Universitaire Vaudois, Lausanne University, Switzerland) |
| SY28-3 | MET as target in advanced NSCLC with cMET aberrant from lab to clinic |
|---|---|
| Yi-Long Wu (Guangdong Lung Cancer Institute, China) |
| SY28-4 | Clinical development of RET inhibitors for RET fusion positive non-small-cell lung cancer (NSCLC) |
|---|---|
| Koichi Goto (Department of Thoracic Oncology, National Cancer Center Hospital East) |
Hematologic Malignancies
Symposium 12 [Hematologic Malignancies]
February 19 (Fri) 8:00-10:00
Cutting Edge AML Treatments
Summary
Gene-panel tests have evolved considerably in hamatologic malignacies as well as in solid cancers. Although no new drug had been available for AML for a long period, FLT3 inhibitors were approved recently. Also, additional approval for a Bcl-2 inhibitor is expected in the near future. In addition, transplantation strategies have been improved significantly, leading to better outcomes. In this symposium, we will focus on the development of gene panel testing for AML in Japan and the latest treatments.
Chairs: |
Kimikazu Yakushijin (Medical Oncology and Hematology, Kobe University Hospital) |
| Takahiro Yamauchi (Department of Hematology and Oncology, University of Fukui) |
| SY12-1 | Identifying targetable dependencies on pro-survival BCL-2 family proteins using BH3 profiling |
|---|---|
| Kristopher Sarosiek (Harvard School of Public Health, USA) |
| SY12-2 | BCL-2 as a Stem Cell Target in Acute Myeloid Leukemia |
|---|---|
| Daniel A. Pollyea (University of Colorado, Department of Medicine, Division of Hematology, USA) |
| SY12-3 | Hematopoietic Transplantation for AML |
|---|---|
| William YK. Hwang (Department of Medical Oncology, National Cancer Centre Singapore and Department of Haematology, Singapore General Hospital, Singapore) |
| SY12-4 | Interim analysis of Hematologic Malignancies (HM)-SCREEN-Japan 01: a mutation profiling multicenter study of patients with AML |
|---|---|
| Kenichi Miyamoto (Department of Medicine, Tokyo Medical and Dental University Graduate School of Medicine) |
| SY12-5 | FLT3 inhibitors for AML |
|---|---|
| Jorge Cortes (Georgia Cancer Center, Augusta University, USA) |
Symposium 29 [Hematologic Malignancies]
February 20 (Sat) 21:00-23:00
Antibody Drug Conjugates for Hematologic Malignancies
Summary
Upon binding to the target antigens expressed on tumor cells, antibody-drug conjugates (ADCs) are incorporated into the cells along with the conjugated cytotoxic drug, thereby showing high cytotoxic effects. In this symposium, the latest developments of novel ADCs for the treatment of AML, MM, DLBCL and T-cell lymphoma will be reported.
Chairs: |
Kazuhito Yamamoto (Aichi Cancer Center) |
| William YK. Hwang (National Cancer Centre Singapore, Singapore) |
| SY29-1 | Review of antibody drug conjugates (ADC) for hematologic malignancies |
|---|---|
| Hiroshi Matsuoka (Division of Bioresource Research and Development, Kobe University Graduate School of Medicine) |
| SY29-2 | Antibody-drug conjugate for acute leukemia |
|---|---|
| Takahiro Yamauchi (Department of Hematology and Oncology, University of Fukui) |
| SY29-3 | Antibody drug conjugates for diffuse large B-cell lymphoma |
|---|---|
| Andrew J. Davies (Experimental Cancer Medicince Centre, Faculty of Medicine, University of Southampton, UK) |
| SY29-4 | Antibody Drug Conjugates in T-cell Lymphoma |
|---|---|
| Steven Horwitz (Department of Medicine, Memorial Sloan Kettering Cancer Center, USA) |
| SY29-5 | Development of antibody drug conjugates in multiple myeloma |
|---|---|
| Shinsuke Iida (Department of Hematology and Oncology, Nagoya City University) |
Symposium 6 [Hematologic Malignancies]
February 18 (Thu) 21:00-23:00
MRD-guided Therapies for Hematologic Malignancies
Summary
Minimum residual disease (MRD) is a potent surrogate marker to predict recurrence and prognosis. In hematopoietic malignancies, MRD is measured at clitical time points during the treatment to make informed decisions on subsequent treatments. In this symposium, we will discuss MRD-based treatment strategies in FLT3-ITD mutation-positive AML, ALL, malignant lymphoma, and MM.
Chairs: |
Junji Suzumiya (Community Hospital Koga Hospital) |
| Jorge Cortes (Georgia Cancer Center, Augusta University, USA) |
| SY6-1 | Potential insights relevant to treatment-free remission based on MRD monitoring in chronic myeloid leukemia |
|---|---|
| Naoto Takahashi (Department of Hematology, Akita University) |
| SY6-2 | FLT3-ITD mutations as a marker of MRD |
|---|---|
| Mark J. Levis (Johns Hopkins University, USA) |
| SY6-3 | MRD monitoring in acute lymphoblastic leukemia treatment |
|---|---|
| Masashi Sanada (Department of Advanced Diagnosis, Clinical Research Center, National Hospital Organization Nagoya Medical Center) |
| SY6-4 | MRD-guided treatment for Hematological malignancies |
|---|---|
| Christiane Pott (Second Department of Medicine, Hematology and Oncology, University Hospital Schleswig-Holstein, Germany) |
| SY6-5 | Treatment options in elderly patients with newly diagnosed MM |
|---|---|
| Thierry Facon (Lille University Hospital, France) |
Breast Cancer
Symposium 23 [Breast Cancer]
February 20 (Sat) 8:00-10:00
Development and Future Perspectives of Immune Checkpoint Inhibitors for Breast Cancer
Summary
In breast cancer, atezolizumab was approved for the treatment of triple-negative advanced recurrent breast cancer following the results of the IMpassion130 trial. This will be the starting point for the expansion of indications to other subtypes, preoperative and postoperative treatments. In addition, more effective use of immune checkpoint inhibitors in breast cancer with “cold” tumors and biomarker studies are needed. On the other hand, management of immune checkpoint inhibitors is necessary to ensure their effective and safe use. In this session, we will comprehensively discuss and deepen our understanding of the nascent field of breast cancer immunotherapy.
Chairs: |
Toshimi Takano (Breast Medical Oncology Department, The Cancer Institute Hospital of JFCR) |
| Fumikata Hara (The Cancer Institute Hospital Of JFCR) |
| SY23-1 | Understanding immune checkpoint inhibitors from a viewpoint of the cancer immunobiology |
|---|---|
| Tomoharu Sugie (Division of Breast Surgery, Kansai Medical University Hospital) |
| SY23-2 | Current standard and future perspectives in metastatic TNBC |
|---|---|
| Hope S. Rugo (University of California San Francisco Medical Center, USA) |
| SY23-3 | Current standard and future perspectives of immune checkpoint inhibitors for early stage TNBC |
|---|---|
| Sibylle Loibl (GBG Forschungs GmbH, Germany) |
| SY23-4 | Combination therapy with immune checkpoint inhibitor and targeted agents in metastatic TNBC and HR-positive breast cancer |
|---|---|
| Yukinori Ozaki (Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research) |
| SY23-5 | Management of Immune-Related Adverse Events (irAE) |
|---|---|
| Emi Noguchi (Department of Breast and Medical Oncology, National Cancer Center Hospital) |
Symposium 16 [Breast Cancer]
February 19 (Fri) 15:40-17:40
De-escalating and Escalating Treatment for Breast Cancer
Summary
Advances in surgery, drugs, and radiation therapy have led to significant improvements in prognosis in breast cancer, but the negative aspects of escalating therapy, such as adverse events, poor quality of life, and increased costs, have become critical issues. In this session, we discuss the evidence, development status, and future needs of de-escalation therapy, taking into account the individual risks of each patient.
Chairs: |
Shigehira Saji (Department of Medical Oncology, Fukushima Medical University) |
| Masato Takahashi (Department of Breast Surgery, NHO Hokkaido Cancer Center) |
| SY16-1 | Advances in early breast cancer (EBC) care from the perspective of Escalation and De-escalation |
|---|---|
| Giuseppe Curigliano (Department of Oncology and Hemato-Oncology, Istituto Europeo di Oncologia, IRCCS and University of Milano, Italy) |
| SY16-2 | De-escalation in surgical oncology |
|---|---|
| Tadahiko Shien (Department of Breast and Endocrine Surgery, Okayama University Hospital) |
| SY16-3 | De-escalation in medical oncology |
|---|---|
| Fumikata Hara (The Cancer Institute Hospital Of JFCR) |
| SY16-4 | De-escalation required for the treatment of advanced breast cancer (ABC) in the future |
|---|---|
| Fatima Cardoso (Breast Unit, Champalimaud Clinical Centre, Portugal) |
| SY16-5 | Problems in clinical trials to evaluate de-escalation |
|---|---|
| Kentaro Sakamaki (Center for Data Science, Yokohama City University) |
Gynecologic Cancer
Symposium 7 [Gynecologic Cancer]
February 18 (Thu) 21:20-23:00
PARP Inhibitor, Anti-angiogenesis, or Both ? -Best Combination Treatments for Ovarian Cancer-
Chairs: |
Kan Yonemori (Department of Breast and Medical Oncology, National Cancer Center) |
| Joyce Liu (Dana-Farber Cancer Institute, USA) |
| SY7-1 | PARP Inhibitor, Anti-Angiogenesis, or Both ? Best Combination for First-Line Ovarian Cancer Treatments |
|---|---|
| Eric Pujade-Lauraine (University Paris Descartes, ARCAGY-GINECO, France) |
| SY7-2 | Combining PARP inhibitors and anti-angiogenics in ovarian cancer: olaparib and cediranib |
|---|---|
| Joyce Liu (Dana-Farber Cancer Institute, USA) |
| SY7-3 | Impact of PARP inhibitor as a front-line therapy for newly diagnosed advanced ovarian cancer |
|---|---|
| Aikou Okamoto (Department of Obstetrics and Gynecology, The Jikei University School of Medicine) |
| SY7-4 | How to use of poly ADP ribose polymerase (PARP) inhibitor or anti-angiogenetic inhibitor for ovarian cancer treatment? |
|---|---|
| Mayu Yunokawa (Department of Gynecology, Department of Medical Oncology, Cancer Institute Hospital of JFCR) |
Symposium 14 [Gynecologic Cancer]
February 19 (Fri) 15:00-16:40
Immune Checkpoint Blockade for Gynecological Malignancies
Chairs: |
Koji Matsumoto (Hyogo Cancer Center Division of Medical Oncology) |
| Antonio Gonzalez-Martin (Department Medical Oncology, Cancer Center Universidad de Navarra, Madrid, Spain) |
| SY14-1 | Immune check point blockade for ovarian cancer |
|---|---|
| Junzo Hamanishi (Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine) |
| SY14-2 | Immune check point blockade for endometrial cancer |
|---|---|
| Shin Nishio (Department of Obstetrics and Gynecology, Kurume University School of Medicine) |
| SY14-3 | Current evidence and future perspectives on immunotherapy for cervical cancer |
|---|---|
| Kosei Hasegawa (Saitama Medical University International Medical Center) |
| SY14-4 | Immune checkpoint blockade for gynecological malignancy |
|---|---|
| Antonio Gonzalez-Martin (Department Medical Oncology, Cancer Center Universidad de Navarra, Madrid, Spain) |
Symposium 37 [Genitourinary Cancer]
February 21 (Sun) 16:30-17:30
A New Era of Genitourinary Cancer Precision Medicine
Summary
Precision medicine will be introduced into urological cancer by 2021 with high probability. In particular, PARP inhibitors for prostate cancer and EGFR inhibitors for urothelial cancer are attracting attention as promising treatment options based on companion diagnoses.
By participating this program, participants will be able to gain the latest knowledge about precision medicine of urological cancers and learn how to use them appropriately in clinical practice.
Chairs: |
Keita Uchino (NTT Medical Center Tokyo, Department of Medical Oncology) |
| Ravindran Kanesvaran (Division of Medical Oncology, National Cancer Centre Singapore, Singapore) |
| SY37-1 | Precision Medicine in Kidney Cancer |
|---|---|
| Yuji Miura (Department of Medical Oncology, Toranomon Hospital) |
| SY37-2 | Precision Medicine in Prostate Cancer |
|---|---|
| Kazutoshi Fujita (Department of Urology, Kindai University Faculty of Medicine) |
| SY37-3 | Precision Medicine in Urothelial Cancer |
|---|---|
| Hiroshi Kitamura (Department of Urology, University of Toyama) |
Head and Neck Cancer
Symposium 11 [Head and Neck Cancer]
February 19 (Fri) 8:00-9:40
New Perspectives on the Treatment of Head and Neck Cancer
Summary
Immune checkpoint inhibitors have become the standard of care as primary treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma. New prospects for future treatment of head and neck cancers are being explored in 1) combination with immune checkpoint inhibitors, 2) combination with radiotherapy for locally advanced cancers, and 3) establishment of new biomarkers.
Chairs: |
Makoto Tahara (Department of Head and Neck Medical Oncology, National Cancer Center Hospital East) |
| Naomi Kiyota (Department of Medical Oncology/Hematology, Kobe University Hospital) |
| SY11-1 | Novel combination immunotherapy for recurrent or metastatic head and neck cancer |
|---|---|
| Ezra Cohen (University of California, San Diego Moores Cancer Center, USA) |
| SY11-2 | Novel drugs including immune checkpoint inhibitors in combination with radiation therapy for head and neck cancer |
|---|---|
| Tetsuo Akimoto (Department of Radiation Oncology, National Cancer Center Hospital East) |
| SY11-3 | Emerging Biomaker for immunotherapy in head and neck caner |
|---|---|
| Yosuke Togashi (Chiba Cancer Center, Research Institute) |
Symposium 33 [Head and Neck Cancer]
February 21 (Sun) 9:00-10:40
New Perspectives on the Treatment of Thyroid Cancer
Summary
Thyroid cancer is a carcinoma with actionable genetic abnormalities, as a result, development of molecular targeting drugs has been very active. In this session, we will provide the latest information regarding the status of approved drugs and the latest therapeutic developments for each tissue type.
Chairs: |
Susumu Okano (Head & Neck medical oncology, National Cancer Center Hospital East) |
| Ken-ichi Ito (Division of Breast and Endocrine Surgery, Department of Surgery, Shinshu University School of Medicine) |
| SY33-1 | Novel Treatment Strategy for Advanced Differentiated Thyroid Cancer |
|---|---|
| Naomi Kiyota (Department of Medical Oncology/Hematology, Cancer Center, Kobe University Hospital) |
| SY33-2 | New Perspectives on the Treatment of Thyroid Cancer: Novel Drugs for Medullary Thyroid Cancer |
|---|---|
| Lori J. Wirth (Massachussts General Hospital, USA) |
| SY33-3 | Novel drugs for anaplastic thyroid cancer |
|---|---|
| Makoto Tahara (Department of Head and Neck Medical Oncology, National Cancer Center Hospital East) |
Rare Cancer/Cancer of Unknown Primary
Symposium 30 [Rare Cancer/Cancer of Unknown Primary]
February 21 (Sun) 8:00-10:00
Immunotherapy and Targeted Therapy for Rare Cancers
Summary
Immunotherapies with immune checkpoint inhibitors have been shown to be effective in many types of cancers but have not been established in rare cancers such as sarcoma, partly because of the difficulty of conducting clinical trials. In this symposium, the therapeutic efficacy of immune checkpoint inhibitors and T-cell therapy in sarcoma as a whole and special subtypes and future strategies for the clinical development of immunotherapy in rare cancers will be discussed.
Chairs: |
Hitoshi Kusaba (Department of Medicine and Comprehensive Biosystemic Science, Graduate Faculty of Medicine, Kyushu University) |
| Shunji Takahashi (Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research) |
| SY30-1 | Immune checkpoint inhibitor for sarcoma |
|---|---|
| William D. Tap (Memorial Sloan Kettering Cancer Center, USA) |
| SY30-2 | Challenge of clinical development for Alveolar Soft Tissue Sarcoma and Clear Cell Sarcoma in Japan |
|---|---|
| Kan Yonemori (National Cancer Center Hospital) |
| SY30-3 | TCR gene-transduced T-cell therapy for sarcoma |
|---|---|
| Shinichi Kageyama (Suzuka Kaisei Hospital/Mie University Graduate School of Medicine) |
| SY30-4 | Molecular target therapy for soft tissue sarcoma |
|---|---|
| Yoichi Naito (Department of General Internal Medicine/Breast and Medical Oncology/Experimental Therapeutics, National Cancer Center Hospital East) |
Translational Research/Clinical Pharmacology
Symposium 13 [Translational Research/Clinical Pharmacology]
February 19 (Fri) 8:00-10:00
Advances in Molecular Therapeutics: Potential Targets and Novel Strategies
Summary
KRAS-mutated tumors, which have been described as undruggable, have received renewed interest with the development of G12C inhibitors. This session delves on the status of therapeutic development for KRAS mutation-positive tumors, including G12C inhibitors. We will also discuss therapeutic development for KRAS mutation-positive tumors, an important subset of non-small cell lung cancer, including drug development for EGFR exon 20 insertion mutations, therapeutic strategies for osimertinib resistance, and the potential for IO combination therapy.
Chairs: |
Kazuto Nishio (Department of Genome Biology, Kindai University Faculty of Medicine) |
| Yasuhiro Koh (Internal Medicine III, Wakayama Medical University) |
| SY13-1 | Bedside to bench approaches to discover mechanism of antiestrogen resistance in breast cancer |
|---|---|
| Carlos Arteaga (UT Southwestern Medical Center, USA) |
| SY13-2 | Targeted therapies in oncogene-addicted NSCLC |
|---|---|
| Christine Lovly (Vanderbilt University, USA) |
| SY13-3 | Novel therapeutic strategies for drug-tolerance in NSCLC with driver oncogenes |
|---|---|
| Tadaaki Yamada (Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine) |
| SY13-4 | Novel Targeted Therapy Development in Triple-Negative Breast Cancer |
|---|---|
| Naoto T. Ueno (Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, USA) |
Symposium 31 [Translational Research/Clinical Pharmacology]
February 21 (Sun) 8:00-10:00
Immunooncology: the Role of the Tumor Microenvironment
Summary
Immunotherapy for malignant tumors is taking a center stage. This session will examine the role of the tumor microenvironment and explores its associations with host microbiomes, metabolism, and responses to immunotherapy and other treatments strategies. We also explore how the tumor microenvironment can be reprogrammed to enhance the therapeutic efficacy of anticancer therapy and examine clinical applications.
Chairs: |
Tomohide Tamura (St. Luke's International Hospital) |
| Yosuke Togashi (Chiba Cancer Center, Research Institute) |
| SY31-1 | Immunological classification revealed genetic bases of immune evasion of microsatellite instability-high colorectal cancers |
|---|---|
| Masahito Kawazu (National Cancer Center Research Institute, Division of Cellular Signaling) |
| SY31-2 | Immunogenic cell death and tumor microenvironment |
|---|---|
| Koji Haratani (Department of Medical Oncology, Kindai University, Faculty of Medicine) |
| SY31-3 | Multiplexed immunohistochemistry for immune profiling |
|---|---|
| Eiichi Sato (Department of Pathology, Institute of Medical Scinece, Tokyo Medical University) |
| SY31-4 | Clonal evolution in the tumor microenvironment |
|---|---|
| Yosuke Togashi (Chiba Cancer Center, Research Institute) |
Cross-sectional Program
Symposium 9 [Cross-sectional Program]
February 19 (Fri) 8:00-9:40
Targeting the Tumor Microenvironment and Microbiome in the New Era of Cancer Immunotherapy
Summary
This session will cover an introductory overview and the latest findings on development strategies for new cancer immunotherapies following immune checkpoint inhibitors, including a focus on new approaches to microbiome-mediated immune modification and modulation of the tumor microenvironment (TME) by expert overseas researchers, followed by summary and problem-solving by discussants, to provide participants with a shared understanding of the barriers and issues related to next-generation cancer immunotherapy.
Chairs: |
Thomas Gajewski (The University of Chicago, USA) |
| Hironobu Minami (Medical Oncology/Hematology, Kobe University Graduate School of Medicine) |
| SY9-1 | Introduction 'Clinical questions on novel cancer immunotherapy' |
|---|---|
| Yuji Miura (Department of Medical Oncology, Toranomon Hospital) |
| SY9-2 | Mechanisms of efficacy versus resistance to anti-PD-1 immunotherapy |
|---|---|
| Thomas Gajewski (The University of Chicago, USA) |
| SY9-3 | Tumor Microbiome Diversity and Composition Influence on Novel Cancer Immunotherapy |
|---|---|
| Florencia McAllister (Department of Clinical Cancer Prevention, Clinical Cancer Genetics Program, The University of Texas MD Anderson Cancer Center, USA) |
| SY9-4 | Development of novel immunotherapy targeting cancer immune evasion |
|---|---|
| Koji Tamada (Department of Immunology, Yamaguchi University Graduate School of Medicine) |
Symposium 22 [Cross-sectional Program]
February 20 (Sat) 8:00-10:00
Tumor Agnostic Drug Development and Approval - A New Phase for Oncology Precision Medicine –
Summary
Even after the tumor agnostic approval of pembrolizumab for advanced solid tumors with high microsatellite instability (MSI-High) and enutrectinib for advanced or recurrent NTRK fusion-positive solid tumors, there are still many unresolved problems for Tissue Agnostic Drug Development/Approval. In this session, we will focus on the current status and challenges of tumor agnostic clinical trials through discussion together with medical oncologists from academia, pharmaceutical companies, statisticians and both the FDA and PMDA regulatory agencies who are working at the forefront of Tissue Agnostic Oncology Drug Development in Japan and the United States.
Chairs: |
Harpreet Singh (Division Director of Division of Oncology 2, the U.S. Food and Drug Administration (FDA), USA) |
| Kenji Tamura (Innovative Cancer Center, Shimane University Hospital) |
| SY22-1 | TA Drug Development Overview/Perspectives |
|---|---|
| Harpreet Singh (Division of Oncology 2, the U.S. Food and Drug Administration (FDA), USA) |
| SY22-2 | From the viewpoint toward clinical development in Japan |
|---|---|
| Hiroya Taniguchi (Department of Gastroenterology and GI Oncology, National Cancer Center Hospital East) |
| SY22-3 | Tumor Agnostic Approval of New Drugs in Oncology : Future Perspectives from Industries |
|---|---|
| David Hyman (Loxo Oncology at Lilly, USA) |
| SY22-4 | Tumor-agnostic Drug Development: From Statistical Viewpoint |
|---|---|
| Takeharu Yamanaka (Department of Biostatistics, Yokohama City University School of Medicine) |
| SY22-5 | Tumor-agnostic Drug Development and Approval from regulatory Authority's Perspective |
|---|---|
| Takahiro Nonaka (Epidemiology Division, Office of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency) |
Clinical Trial Facilitation Program
Symposium 32 [Clinical Trial Facilitation Program]
February 21 (Sun) 9:00-11:00
Adjuvant Clinical Trials in the Precision Medicine Era
Summary
It is highly expected that liquid biopsy will be widely available soon in general clinical practice, and accumulating data have been published in many cancer types with regard to the role of liquid biopsy for predicting recurrence after curative surgery. In this symposium, we will understand the history and current status of "tissue biopsy" gene tests for predicting tumor recurrence at first, and then review current available evidence for "liquid biopsy" tests. Further, we will discuss the optimal design and analysis of clinical trials for developing personalized treatment with liquid biopsies. These discussion will help to understand the future development of liquid biopsy.
Chairs: |
Takeharu Yamanaka (Department of Biostatistics, Yokohama City University School of Medicine) |
| Kazuto Nishio (Department of Genome Biology, Kindai University Faculty of Medicine) |
| SY32-1 | Clinical Development of Gene Expression Assay (Oncotype DX) and Future Challenges in a ctDNA-based Test Era |
|---|---|
| Calvin Chao (Exact Sciences Corporation, USA) |
| SY32-2 | Innovative Challenge on Circulating Tumor DNA (ctDNA) - Tailored Adjuvant Treatment: CIRCULATE-Japan |
|---|---|
| Takayuki Yoshino (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East) |
| SY32-3 | Lesson from International Collaborattive Adjuvant Clinical Trials |
|---|---|
| Qian Shi (Department of Quantitative Health Sciences, Mayo Clinic, USA) |
Patient Advocacy/Survivorship
Symposium 1 [Patient Advocacy/Survivorship]
February 18 (Thu) 16:00-18:00
Implementing Strategies of Cancer Survivorship Care
Summary
Cancer survivorship care is a multidisciplinary approach that includes long-term follow up, management of adverse events, health promotion and effective communication. Implementing and disseminating information to integrate evidence-based health interventions into clinical and community settings is essential for improving patient outcomes and benefiting population health. Key to collaboration and cooperation is the ability of share information and resources including acute care hospitals, clinics, local governments, NPO/NGOs, and private sectors, etc. In this session, we will learn from Australian experiences and discuss ways to implement effective survivorship care in Japan.
Chairs: |
Kiyotaka Watanabe (Division of Medical Oncology, Department of Medicine, Teikyo University) |
| Miyako Takahashi (Japan Cancer Survivorship Network) |
| SY1-1 | Overview of Strategies of Cancer Survivorship Care in Japan |
|---|---|
| Kiyotaka Watanabe (Division of Medical Oncology, Department of Medicine, Teikyo University) |
| SY1-2 | Improving care and outcomes for cancer survivors: an Australian experience |
|---|---|
| Michael Jefford (Peter MacCallum Cancer Centre, Australia) |
| SY1-3 | The implementation of survivorship care in community |
|---|---|
| Miyako Tsuchiya (Division of Cancer Survivorship Research, Center for Cancer Control and Information Services, National Cancer Center ) |
| SY1-4 | Lessons from community engagement activities of cancer survivors |
|---|---|
| Miki Akiyama (Faculty of Environment and Information Studies, Keio University) |
